{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T12:21:29Z","timestamp":1762431689213},"reference-count":11,"publisher":"Pharmaceutical Society of Japan","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biological & Pharmaceutical Bulletin","Biol. Pharm. Bull."],"published-print":{"date-parts":[[2019,7,1]]},"DOI":"10.1248\/bpb.b19-00001","type":"journal-article","created":{"date-parts":[[2019,6,30]],"date-time":"2019-06-30T22:03:18Z","timestamp":1561932198000},"page":"1098-1101","source":"Crossref","is-referenced-by-count":2,"title":["Factors That Affect Continuation of Antipsychotic Long-Acting Injections"],"prefix":"10.1248","volume":"42","author":[{"given":"Miko","family":"Taniguchi","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacy, Fujita Health University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masakazu","family":"Hatano","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Fujita Health University School of Medicine"},{"name":"Department of Psychiatry, Fujita Health University School of Medicine"},{"name":"Laboratory of Clinical Pharmacy Practices, Meijo University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Kamei","sequence":"additional","affiliation":[{"name":"Laboratory of Clinical Pharmacy Practices, Meijo University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Risa","family":"Inagaki","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Fujita Health University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigeki","family":"Yamada","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Fujita Health University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"163","reference":[{"key":"1","unstructured":"1) Kishimoto T, Nitta M, Borenstein M, Kane JM, Correll CU. Long-acting injectable versus<\/i> oral antipsychotics in schizophrenia: a systematic review and meta-analysis of mirror-image studies. J. Clin. Psychiatry<\/i>, 74<\/b>, 957\u2013965 (2013)."},{"key":"2","unstructured":"2) Kishimoto T, Robenzadeh A, Leucht C, Leucht S, Watanabe K, Mimura M, Borenstein M, Kane JM, Correll CU. Long-acting injectable vs.<\/i> oral antipsychotics for relapse prevention in schizophrenia: a meta-analysis of randomized trials. Schizophr. Bull.<\/i>, 40<\/b>, 192\u2013213 (2014)."},{"key":"3","unstructured":"3) Heres S, Hamann J, Mendel R, Wickelmaier F, Pajonk FG, Leucht S, Kissling W. Identifying the profile of optimal candidates for antipsychotic depot therapy: a cluster analysis. Prog. Neuropsychopharmacol. Biol. Psychiatry<\/i>, 32<\/b>, 1987\u20131993 (2008)."},{"key":"4","unstructured":"4) Taylor DM, Fischetti C, Sparshatt A, Thomas A, Bishara D, Cornelius V. Risperidone long-acting injection: a prospective 3-year analysis of its use in clinical practice. J. Clin. Psychiatry<\/i>, 70<\/b>, 196\u2013200 (2009)."},{"key":"5","unstructured":"5) Taylor DM, Sparshatt A, O\u2019Hagan M, Dzahini O. Paliperidone palmitate: factors predicting continuation with treatment at 2 years. Eur. Neuropsychopharmacol.<\/i>, 26<\/b>, 2011\u20132017 (2016)."},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Attard A, Olofinjana O, Cornelius V, Curtis V, Taylor D. Paliperidone palmitate long-acting injection-prospective year-long follow-up of use in clinical practice. Acta Psychiatr. Scand.<\/i>, 130<\/b>, 46\u201351 (2014).","DOI":"10.1111\/acps.12201"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Inada T, Inagaki A. Psychotropic dose equivalence in Japan. Psychiatry Clin. Neurosci.<\/i>, 69<\/b>, 440\u2013447 (2015).","DOI":"10.1111\/pcn.12275"},{"key":"8","unstructured":"8) Taylor DM, Young C, Patel MX. Prospective 6-month follow-up of patients prescribed risperidone long-acting injection: factors predicting favourable outcome. Int. J. Neuropsychopharmacol.<\/i>, 9<\/b>, 685\u2013694 (2006)."},{"key":"9","unstructured":"9) Baandrup L, Gasse C, Jensen VD, Glenthoj BY, Nordentoft M, Lublin H, Fink-Jensen A, Lindhardt A, Mortensen PB. Antipsychotic polypharmacy and risk of death from natural causes in patients with schizophrenia: a population-based nested case-control study. J. Clin. Psychiatry<\/i>, 71<\/b>, 103\u2013108 (2010)."},{"key":"10","unstructured":"10) Taylor DM, Young CL, Mace S, Patel MX. Early clinical experience with risperidone long-acting injection: a prospective, 6-month follow-up of 100 patients. J. Clin. Psychiatry<\/i>, 65<\/b>, 1076\u20131083 (2004)."},{"key":"11","unstructured":"11) Takekita Y, Koshikawa Y, Fabbri C, Sakai S, Sunada N, Onohara A, Nishida K, Yoshimura M, Kato M, Serretti A, Kinoshita T. Cognitive function and risperidone long-acting injection vs.<\/i> paliperidone palmitate in schizophrenia: a 6-month, open-label, randomized, pilot trial. BMC Psychiatry<\/i>, 16<\/b>, 172 (2016)."}],"container-title":["Biological and Pharmaceutical Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/42\/7\/42_b19-00001\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,6]],"date-time":"2019-07-06T03:21:03Z","timestamp":1562383263000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/42\/7\/42_b19-00001\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,1]]},"references-count":11,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1248\/bpb.b19-00001","relation":{},"ISSN":["0918-6158","1347-5215"],"issn-type":[{"value":"0918-6158","type":"print"},{"value":"1347-5215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,1]]}}}